BioAge Labs insider sells 42,350 and 20,216 shares

BioAge Labs, Inc. principal accounting officer Shane Barton exercised stock options and sold shares of common stock in late June.

Rhea-AI Filing Summary

BioAge Labs, Inc. principal accounting officer Shane Barton exercised stock options and sold shares of common stock in late June. He exercised options covering 59,934 shares at strike prices between $4.30 and $10.85 per share, then sold a total of 62,566 shares in open-market transactions at weighted average prices around $25 per share. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025, and after these trades he reported holding no shares of common stock directly.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 18 txns

Insider Barton Shane

Role Principal Accounting Officer

Sold 62,566 shs ($1.58M)

Approx. gross sale proceeds $1.58M

Approx. exercise cost $395K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	4,290	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	4,000	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	4,065	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	7,861	$0.00	$0.00
Exercise	Common Stock	4,290	$10.85	$47K
Exercise	Common Stock	4,000	$8.39	$34K
Exercise	Common Stock	4,065	$4.30	$17K
Exercise	Common Stock	7,861	$4.38	$34K
Sale	Common Stock	20,216	$25.1868	$509K
Exercise	Stock Option (Right to Buy)	9,301	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	7,261	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	8,958	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	14,198	$0.00	$0.00
Exercise	Common Stock	9,301	$10.85	$101K
Exercise	Common Stock	7,261	$8.39	$61K
Exercise	Common Stock	8,958	$4.30	$39K
Exercise	Common Stock	14,198	$4.38	$62K
Sale	Common Stock	42,350	$25.2084	$1.07M

Holdings After Transaction: Stock Option (Right to Buy) — 125,233 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (7)

1. F1. The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.79 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
3. F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.42 per share, inclusive.
4. F4. The option vested as to 1/4th of the total award on September 25, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
5. F5. The option vested as to 1/4th of the total award on October 17, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
6. F6. The option vested as to 1/4th of the total award on October 26, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
7. F7. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2026 - 04:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barton Shane

(Last) (First) (Middle)

C/O BIOAGE LABS, INC.

5885 HOLLIS STREET, SUITE 370

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioAge Labs, Inc. [ BIOA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/29/2026		M(1)		9,301	A	$10.85	11,933	D
Common Stock	06/29/2026		M(1)		7,261	A	$8.39	19,194	D
Common Stock	06/29/2026		M(1)		8,958	A	$4.3	28,152	D
Common Stock	06/29/2026		M(1)		14,198	A	$4.38	42,350	D
Common Stock	06/29/2026		S(1)		42,350	D	$25.2084(2)	0	D
Common Stock	06/30/2026		M(1)		4,290	A	$10.85	4,290	D
Common Stock	06/30/2026		M(1)		4,000	A	$8.39	8,290	D
Common Stock	06/30/2026		M(1)		4,065	A	$4.3	12,355	D
Common Stock	06/30/2026		M(1)		7,861	A	$4.38	20,216	D
Common Stock	06/30/2026		S(1)		20,216	D	$25.1868(3)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.85	06/29/2026		M(1)			9,301	(4)	09/26/2033	Common Stock	9,301	$0	17,589	D
Stock Option (Right to Buy)	$8.39	06/29/2026		M(1)			7,261	(5)	04/16/2034	Common Stock	7,261	$0	21,016	D
Stock Option (Right to Buy)	$4.3	06/29/2026		M(1)			8,958	(6)	12/17/2034	Common Stock	8,958	$0	31,042	D
Stock Option (Right to Buy)	$4.38	06/29/2026		M(1)			14,198	(7)	02/17/2035	Common Stock	14,198	$0	75,802	D
Stock Option (Right to Buy)	$10.85	06/30/2026		M(1)			4,290	(4)	09/26/2033	Common Stock	4,290	$0	13,299	D
Stock Option (Right to Buy)	$8.39	06/30/2026		M(1)			4,000	(5)	04/16/2034	Common Stock	4,000	$0	17,016	D
Stock Option (Right to Buy)	$4.3	06/30/2026		M(1)			4,065	(6)	12/17/2034	Common Stock	4,065	$0	26,977	D
Stock Option (Right to Buy)	$4.38	06/30/2026		M(1)			7,861	(7)	02/17/2035	Common Stock	7,861	$0	67,941	D

Explanation of Responses:

1. The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.79 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.42 per share, inclusive.

4. The option vested as to 1/4th of the total award on September 25, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

5. The option vested as to 1/4th of the total award on October 17, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

6. The option vested as to 1/4th of the total award on October 26, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

7. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

	/s/ Dov A. Goldstein as attorney-in-fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)